NPPA Caps Retail Prices Of 2 Formulations

Mumbai : The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 2 formulations under Drugs Prices Control Order (DPCO) – 2013 based on the decision of 86th authority meeting dated April 28, 2021.

The formulations are budesonide tablet and dexamethasone tablet.

The manufacturer of these formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified. The manufacturer may add goods and services tax only if they have paid actually or it is payable to the government on the retail price as prescribed by NPPA.

The retail price for a pack of these formulations shall be arrived at by the concerned manufacturer in accordance with the retail price specified as per provisions contained in paragraph 11 of the DPCO, 2013.

The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller (SDC) and dealers.

As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

The retail price fixed is applicable only to the individual manufacturer/marketer as specified i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO 2013.

In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

  • Related Posts

    Over-the-counter sale of cough syrup barred

    Following the Drugs Rules amendment, lozenges, pills, and tablets for cough will still be available over the counter; 24 children in M.P. died after consuming adulterated cough syrup last year…

    FDA seals Bhiwandi-based cosmetic factory for misleading claims, fake address

    Mumbai: On Tuesday, the FDA said it had sealed a cosmetic manufacturing factory in Bhiwandi for allegedly misleading consumers on e-commerce platforms by labelling its products as sulfate-free and paraben-free. The stock…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Over-the-counter sale of cough syrup barred

    Over-the-counter sale of cough syrup barred

    FDA seals Bhiwandi-based cosmetic factory for misleading claims, fake address

    FDA seals Bhiwandi-based cosmetic factory for misleading claims, fake address

    Yashoda Medicity’s AI-enabled E- ICU poised to make Quality Critical Care Universal

    Yashoda Medicity’s AI-enabled E- ICU poised to make Quality Critical Care Universal

    Licences no shield in NDPS cases: HC refuses bail in 1.37 crore tablets seizure

    Licences no shield in NDPS cases: HC refuses bail in 1.37 crore tablets seizure

    No cough syrups without a doctor’s prescription – New rules announced

    No cough syrups without a doctor’s prescription – New rules announced

    CSIR-IIIM launches two-month certificate course On cGMP-compliant herbal drug manufacturing

    CSIR-IIIM launches two-month certificate course On cGMP-compliant herbal drug manufacturing